Healthcare & Biotech

Celgene (CELG), Valeant (VRX), Acadia (ACAD), & Gilead Sciences (GILD) Outlook On Drug Pricing Concerns

How Donald Trump’s stance on drug prices will affect each of BNL Finance covered biotechs: CELG, VRX, ACAD, JAZZ, and GILD.

Also posted in Members, Stock Ratings, Timely Analysis | | Tagged , , , , , , , , , | Leave a comment

While I Finally Sold RAD Stock & Bought WBA Stock Ahead of Walgreens Rite Aid Merger

After owning RAD stock since $1.23 and being overly bullish in favor of the Walgreens Rite Aid merger, I finally divested the stake and moved to WBA stock.

Also posted in Hot Stocks, Members, Mergers & Acquisitions | | Tagged , , , | Leave a comment

Why Investors Are Making A Huge Mistake With Valeant Pharmaceuticals (NYSE:VRX) Stock

BNL Finance is upgrading VRX stock after the ultimate asset sale goes unrealized. Valeant Pharmaceuticals is poised to deliver significant shareholder value

Also posted in Members, Mergers & Acquisitions | | Tagged , | Leave a comment

Valeant Pharmaceuticals Sends Strong Message to VRX Stock Owners & Short Sellers With Dendreon Divestment

Valeant Pharmaceuticals divestment of Dendreon illustrates the tremendous value in VRX stock, while reducing the need to sell its more valuable assets.

Also posted in Members, Mergers & Acquisitions | | Tagged , | Leave a comment

Why Acadia Pharmaceuticals (ACAD) Will Get More Than $44 From Pfizer (PFE)

Why ACAD stock will be the next Medivation. Pfizer, Gilead, Teva, Bristol-Myers, Otsuka & AbbVie are all companies that would want Nuplazid & Acadia Pharma

Also posted in Members, Mergers & Acquisitions | | Tagged , , , , , , , , | 1 Comment

Acadia Pharmaceuticals Inc (ACAD) Outlook With Lewy Body Dementia & Off Label Nuplazid Use

Acadia Pharmaceuticals’ Nuplazid is reportedly seeing a rise in off label use, specifically With Lewy Body Dementia. That’s great news for ACAD stock.

Also posted in BNL Reports | | Tagged , | 3 Comments

Thoughts on RAD Stock’s Drop from $8.60 to $8.39 Despite Inevitable Rite Aid Buyout

RAD stock is about equal risk to cash and will significantly outperform stocks in early 2017. That makes Rite Aid stock’s $0.20 loss very attractive.

Also posted in Members, Mergers & Acquisitions | | Tagged , , , , | Leave a comment